



RPG LIFE SCIENCES LIMITED
Regd. Off.: RPG House
463, Dr. Annie Besant Road
Worli, Mumbai 400030, India
Tel: +91-22-24981650 / 66606375
Fax: +91-22-24970127
Email: info@rpglifesciences.com
www.rpglifesciences.com
CIN : L24232MH2007PLC169354

April 29, 2023

National Stock Exchange of India Limited
Plot No. C/1, "G" Block, Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Security Code: 532983

Dear Sirs /Madam,

Sub: Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Audited Financial Results for the quarter and year ended March 31, 2023.

Kindly take this information on record.

Thanking you,

Yours Sincerely,

For RPG Life Sciences Limited

RAJESH

RAMESH

SHIRAMBEKAR

Digitally signed by RAJESH
RAMESH SHIRAMBEKAR
Date: 2023.04.29 14:04:01
+05'30'

Rajesh Shirambekar

Head – Legal & Company Secretary

Encl. as above



RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.
CIN: L24232MH2007PLC169354;
Tel: +91-22-2498 1650; Fax: +91-22-2497 0127
E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com

Extract of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2023

Particulars	(Rs. in Lakhs)			
	Quarter ended		Year ended	
	March 31, 2023 (Audited)	March 31, 2022 (Audited)	March 31, 2023 (Audited)	March 31, 2022 (Audited)
1 Total Income from Operations	12,033	10,506	51,761	44,315
2 Net Profit for the period (before tax, exceptional and extraordinary items)	1,381	1,093	9,168	7,317
3 Net Profit for the period before tax (after exceptional and extraordinary items)	1,381	1,093	9,168	7,317
4 Net Profit for the period after tax (after exceptional and extraordinary items)	1,035	752	6,764	5,148
5 Total Comprehensive Income for the period (Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	1,082	736	6,771	5,123
6 Paid-up equity share capital (Face Value Rs.8/- each)	1,323	1,323	1,323	1,323
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year	-	-	29,437	24,254
8 Earnings Per Share (Rs./- each) - (not annualised for quarter):				
Basic (in Rs.)	6.26	4.55	49.80	31.13
Diluted (in Rs.)	6.26	4.55	49.80	31.13

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 26, 2023.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- The Board of Directors has recommended a final dividend of Rs. 12 (Rupees Twelve only) per equity share (150% on the face value of Rs 8 each) for the financial year 2022-23, subject to approval of shareholders at the ensuing Annual General Meeting.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on Stock Exchange websites viz. (www.nseindia.com and www.bseindia.com) and on Company's website (www.rpglifesciences.com).

For RPG Life Sciences Limited
Yugal Sikri
Managing Director
DIN: 07576560

Place : Mumbai
Date : April 28, 2023

